Abstract 494P
Background
The study aimed to assess the effects of a modified electric field patch operation method on scalp adverse reactions in glioblastoma patients undergoing tumor treating fields (TTFields).
Methods
A total of 73 glioblastoma patients who received TTFields between May 2019 and July 2022 were included in the study. The control group consisted of 36 patients treated with the conventional electric field patch operation method before April 2021, while the modified group included 37 patients treated after May 2021 using an improved technique for adhesion and removal of the electric field patch. The study conducted a comparison between two groups regarding the incidence of adverse scalp reactions and compliance with TTFields.
Results
The modified group exhibited significantly lower rates of scalp pruritus (P=0.0246), contact dermatitis (P=0.0253), and skin ulceration (P=0.0299) compared to the control group. Additionally, compliance with TTFields was notably higher in the modified group (81.1%) than in the control group (52.8%) with a statistically significant difference (P=0.0101). Furthermore, the incidence of adverse scalp reactions displayed seasonal variability, with the highest rates observed in summer (56.16%) and the lowest in winter (8.22%). Following the implementation of the adjusted electric field patch operation technique, a notable decrease in the incidence of adverse scalp reactions during the summer (P=0.0002), autumn (P=0.0411), and spring (P=0.0342) seasons was observed.
Conclusions
The utilization of this modified method has demonstrated efficacy in mitigating scalp adverse reactions, minimizing treatment disruptions, and enhancing adherence to TTFields therapy among patients.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
547P - Artificial Intelligence-powered analysis of the tumor immune microenvironment in primary and metastatic colorectal cancer
Presenter: Elio Adib
Session: Poster session 16
548P - Simplified immune score based on CD8+ T-cells at the invasive margin provides comparable prognostic value to immune scores in non-metastatic colorectal cancer
Presenter: Durgesh Wankhede
Session: Poster session 16
549P - Combined morphometric immune signatures define the prognosis of patients with resectable colorectal liver metastases
Presenter: Markus Moehler
Session: Poster session 16
550P - The impact of mismatch repair status on accuracy of clinical staging in upfront resected stage II/III rectal cancer in the Netherlands
Presenter: Renee Lunenberg
Session: Poster session 16
551P - Efficacy prediction of chemoradiotherapy plus anti-PD-1/PD-L1 treatment by magnetic resonance imaging in MSS locally advanced rectal cancer
Presenter: Wentao Tang
Session: Poster session 16
552P - Baseline imaging biomarkers to predict outcomes in locally advanced colon cancer (LACC): Data from the FOxTROT international randomised-controlled trial
Presenter: James Platt
Session: Poster session 16
553P - Association of ctDNA-based MRD detection and MRD clearance with short-term overall survival in patients with resectable colorectal cancer: Updated analysis of CIRCULATE-Japan GALAXY
Presenter: JUN NAGATA
Session: Poster session 16
555P - Association between copy number aberration and ctDNA MRD in colorectal cancer: CIRCULATE-Japan GALAXY
Presenter: TOMOYA HARIMA
Session: Poster session 16